Intuitive Surgical, Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US46120E6023
USD
568.63
0.91 (0.16%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Intuitive Surgical, Inc. stock-summary
stock-summary
Intuitive Surgical, Inc.
Pharmaceuticals & Biotechnology
Intuitive Surgical, Inc. (Intuitive) designs, manufactures and markets da Vinci Surgical Systems, and related instruments and accessories. The Company's da Vinci Surgical System consists of a surgeon's console, a patient-side cart and a vision system. The da Vinci Surgical System translates a surgeon's hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. The da Vinci Surgical System provides its operating surgeons with control, range of motion, tissue manipulation capability and three-dimensional (3-D), high-definition (HD) vision. Intuitive has four generations of da Vinci Surgical System: the da Vinci Xi Surgical System, the da Vinci Si Surgical System, the da Vinci S Surgical System and the standard da Vinci Surgical System. The Company's instruments and accessories include EndoWrist Instruments and da Vinci Single-Site.
Company Coordinates stock-summary
Company Details
1020 Kifer Rd , SUNNYVALE CA : 94086-5301
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 220 Schemes (35.76%)

Foreign Institutions

Held by 619 Foreign Institutions (22.25%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Craig Barratt
Chairman of the Board
Dr. Gary Guthart
President, Chief Executive Officer, Director
Mr. Joseph Beery
Director
Ms. Amal Johnson
Independent Director
Dr. Don Kania
Independent Director
Dr. Amy Ladd
Independent Director
Mr. Keith Leonard
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2,440 Million
(Quarterly Results - Jun 2025)
Net Profit:
664 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 168,484 Million (Large Cap)

stock-summary
P/E

80.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.30

stock-summary
Return on Equity

14.91%

stock-summary
Price to Book

9.44